tiprankstipranks
Immunocore Holdings Plc (IMCR)
NASDAQ:IMCR
US Market
IMCR
Immunocore Holdings
RESEARCH TOOLSreports

Immunocore Holdings (IMCR) Stock Forecast & Price Target

247 Followers
See the Price Targets and Ratings of:

IMCR Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Immunocore
Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMCR Stock 12 Month Forecast

Average Price Target

$66.38
▲(107.70% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Immunocore Holdings in the last 3 months. The average price target is $66.38 with a high forecast of $100.00 and a low forecast of $38.00. The average price target represents a 107.70% change from the last price of $31.96.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","64":"$64","101":"$101","45.5":"$45.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,45.5,64,82.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,35.67076923076923,41.03153846153846,46.392307692307696,51.75307692307692,57.113846153846154,62.47461538461539,67.83538461538461,73.19615384615385,78.55692307692307,83.9176923076923,89.27846153846154,94.63923076923078,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,33.08461538461538,35.85923076923077,38.63384615384615,41.40846153846154,44.18307692307692,46.957692307692305,49.732307692307685,52.50692307692307,55.28153846153846,58.05615384615384,60.83076923076922,63.60538461538461,{"y":66.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,30.90153846153846,31.493076923076924,32.08461538461538,32.676153846153845,33.26769230769231,33.85923076923077,34.45076923076923,35.042307692307695,35.63384615384615,36.22538461538461,36.816923076923075,37.40846153846154,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.67,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$66.38Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on IMCR
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$60
Buy
87.73%
Upside
Reiterated
04/02/26
Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Immunocore Holdings (IMCR)
H.C. Wainwright Analyst forecast on IMCR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$100
Buy
212.89%
Upside
Reiterated
03/04/26
Immunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target
Mizuho Securities Analyst forecast on IMCR
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$38
Hold
18.90%
Upside
Reiterated
02/26/26
Immunocore Holdings (IMCR) Gets a Hold from Mizuho Securities
Oppenheimer Analyst forecast on IMCR
Jeff Jones
Oppenheimer
Oppenheimer
$86
Buy
169.09%
Upside
Reiterated
02/26/26
Oppenheimer Remains a Buy on Immunocore Holdings (IMCR)
Morgan Stanley Analyst forecast on IMCR
Sean Laaman
Morgan Stanley
Morgan Stanley
$40
Hold
25.16%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (NASDAQ: IMCR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Schrodinger (NASDAQ: SDGR)
Goldman Sachs Analyst forecast on IMCR
Rajan Sharma
Goldman Sachs
Goldman Sachs
$74→$72
Buy
125.28%
Upside
Reiterated
02/26/26
TD Cowen Analyst forecast on IMCR
Tyler Van Buren
TD Cowen
TD Cowen
$60
Buy
87.73%
Upside
Reiterated
02/25/26
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
Needham Analyst forecast on IMCR
Gil Blum
Needham
Needham
$75
Buy
134.67%
Upside
Reiterated
02/25/26
Analysts Are Bullish on Top Healthcare Stocks: Alkermes (ALKS), Immunocore Holdings (IMCR)
UBS Analyst forecast on IMCR
Michael Yee
UBS
UBS
$55
Buy
72.09%
Upside
Initiated
01/06/26
Immunocore upgraded to Buy from Sell at UBSImmunocore upgraded to Buy from Sell at UBS
Guggenheim Analyst forecast on IMCR
Paul Jeng
Guggenheim
Guggenheim
―
Hold
―
Initiated
09/17/25
Immunocore assumed with a Neutral at GuggenheimImmunocore assumed with a Neutral at Guggenheim
Jefferies Analyst forecast on IMCR
Kelly Shi
Jefferies
Jefferies
$48
Buy
50.19%
Upside
Initiated
08/24/25
Immunocore Holdings (IMCR) Receives a New Rating from Jefferies
Leerink Partners Analyst forecast on IMCR
Jonathan Chang
Leerink Partners
Leerink Partners
$67→$60
Buy
87.73%
Upside
Reiterated
08/11/25
Leerink Partners Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Barclays Analyst forecast on IMCR
Peter Lawson
Barclays
Barclays
$52
Buy
62.70%
Upside
Reiterated
08/08/25
Barclays Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Deutsche Bank Analyst forecast on IMCR
James Shin
Deutsche Bank
Deutsche Bank
$65
Buy
103.38%
Upside
Initiated
05/27/25
Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank
J.P. Morgan Analyst forecast on IMCR
Jessica Fye
J.P. Morgan
J.P. Morgan
$50
Buy
56.45%
Upside
Reiterated
04/11/25
J.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on IMCR
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$60
Buy
87.73%
Upside
Reiterated
04/02/26
Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Immunocore Holdings (IMCR)
H.C. Wainwright Analyst forecast on IMCR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$100
Buy
212.89%
Upside
Reiterated
03/04/26
Immunocore: Strong KIMMTRAK Execution, Robust Late-Stage Pipeline, and Cash-Funded Catalysts Support Buy Rating and $100 Target
Mizuho Securities Analyst forecast on IMCR
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$38
Hold
18.90%
Upside
Reiterated
02/26/26
Immunocore Holdings (IMCR) Gets a Hold from Mizuho Securities
Oppenheimer Analyst forecast on IMCR
Jeff Jones
Oppenheimer
Oppenheimer
$86
Buy
169.09%
Upside
Reiterated
02/26/26
Oppenheimer Remains a Buy on Immunocore Holdings (IMCR)
Morgan Stanley Analyst forecast on IMCR
Sean Laaman
Morgan Stanley
Morgan Stanley
$40
Hold
25.16%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (NASDAQ: IMCR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Schrodinger (NASDAQ: SDGR)
Goldman Sachs Analyst forecast on IMCR
Rajan Sharma
Goldman Sachs
Goldman Sachs
$74→$72
Buy
125.28%
Upside
Reiterated
02/26/26
TD Cowen Analyst forecast on IMCR
Tyler Van Buren
TD Cowen
TD Cowen
$60
Buy
87.73%
Upside
Reiterated
02/25/26
Immunocore: Sustained Kimmtrak Momentum and Pipeline Catalysts Support Buy Rating
Needham Analyst forecast on IMCR
Gil Blum
Needham
Needham
$75
Buy
134.67%
Upside
Reiterated
02/25/26
Analysts Are Bullish on Top Healthcare Stocks: Alkermes (ALKS), Immunocore Holdings (IMCR)
UBS Analyst forecast on IMCR
Michael Yee
UBS
UBS
$55
Buy
72.09%
Upside
Initiated
01/06/26
Immunocore upgraded to Buy from Sell at UBSImmunocore upgraded to Buy from Sell at UBS
Guggenheim Analyst forecast on IMCR
Paul Jeng
Guggenheim
Guggenheim
―
Hold
―
Initiated
09/17/25
Immunocore assumed with a Neutral at GuggenheimImmunocore assumed with a Neutral at Guggenheim
Jefferies Analyst forecast on IMCR
Kelly Shi
Jefferies
Jefferies
$48
Buy
50.19%
Upside
Initiated
08/24/25
Immunocore Holdings (IMCR) Receives a New Rating from Jefferies
Leerink Partners Analyst forecast on IMCR
Jonathan Chang
Leerink Partners
Leerink Partners
$67→$60
Buy
87.73%
Upside
Reiterated
08/11/25
Leerink Partners Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Barclays Analyst forecast on IMCR
Peter Lawson
Barclays
Barclays
$52
Buy
62.70%
Upside
Reiterated
08/08/25
Barclays Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)
Deutsche Bank Analyst forecast on IMCR
James Shin
Deutsche Bank
Deutsche Bank
$65
Buy
103.38%
Upside
Initiated
05/27/25
Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank
J.P. Morgan Analyst forecast on IMCR
Jessica Fye
J.P. Morgan
J.P. Morgan
$50
Buy
56.45%
Upside
Reiterated
04/11/25
J.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunocore Holdings

3 Months
xxx
Success Rate
6/13 ratings generated profit
46%
Average Return
+8.08%
reiterated a xxx
 rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of +8.08% per trade.
1 Year
Jessica FyeJ.P. Morgan
Success Rate
7/13 ratings generated profit
54%
Average Return
+9.57%
reiterated a buy rating 12 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +9.57% per trade.
2 Years
xxx
Success Rate
6/13 ratings generated profit
46%
Average Return
+1.10%
reiterated a xxx
 rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of +1.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMCR Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
11
11
10
10
8
Buy
6
3
1
0
0
Hold
31
29
27
23
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
43
38
33
18
In the current month, IMCR has received 8 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. IMCR average Analyst price target in the past 3 months is 66.38.
Each month's total comprises the sum of three months' worth of ratings.

IMCR Financial Forecast

IMCR Earnings Forecast

Next quarter’s earnings estimate for IMCR is -$0.27 with a range of -$0.42 to -$0.10. The previous quarter’s EPS was $0.00. IMCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMCR is -$0.27 with a range of -$0.42 to -$0.10. The previous quarter’s EPS was $0.00. IMCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Sales Forecast

Next quarter’s sales forecast for IMCR is $107.00M with a range of $99.25M to $112.30M. The previous quarter’s sales results were $103.05M. IMCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.
Next quarter’s sales forecast for IMCR is $107.00M with a range of $99.25M to $112.30M. The previous quarter’s sales results were $103.05M. IMCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMCR has Performed in-line its overall industry.

IMCR Stock Forecast FAQ

What is IMCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunocore Holdings Plc’s 12-month average price target is 66.38.
    What is IMCR’s upside potential, based on the analysts’ average price target?
    Immunocore Holdings Plc has 107.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMCR a Buy, Sell or Hold?
          Immunocore Holdings Plc has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Immunocore Holdings Plc’s price target?
            The average price target for Immunocore Holdings Plc is 66.38. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $38.00. The average price target represents 107.70% Increase from the current price of $31.96.
              What do analysts say about Immunocore Holdings Plc?
              Immunocore Holdings Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of IMCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.